العلاج الجهازي لسرطان الشرج المتقدم/النقيلي في المرحلة الرابعة للمرضى المؤهلين

References

DOI: 10.1016/j.annonc.2021.06.015

• Eligible for systemic treatment
• Otherwise fit patients with symptomatic metastatic or recurrent disease not amenable to surgery should be considered for ChT.
• Second-line: cisplatin–5-FU, carboplatin, doxorubicin, taxane, irinotecan ± cetuximab or combinations [III, B]
• PD-L1 inhibitors may be considered where possible in patients who have progressed on first-line therapy in clinical trials [III, B].
• Cisplatin in combination with 5-FU/capecitabine, carboplatin or docetaxel-based combinations are alternatives in patients with ChT-naive advanced anal cancer [III, B].